Selective oocyte retrieval: a new approach to ovarian hyperstimulation

Belaïsch-Allart, J.; Belaïsch, J; Hazout, A.; Testart, J; Frydman, René

doi:10.1016/s0015-0282(16)60201-7

Cited by 22 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, selective follicular reduction can be followed by immediate fertilization and embryo cryopreservation (Belaisch-Allart et al, 1988;Zusterzeel et al, 1996). Although embryo cryopreservation is a more established technique, oocyte vitrification holds important benefits.…”

Section: Discussionmentioning

confidence: 99%

Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use

Stoop

Landuyt

Paquay³

et al. 2010

Human Reproduction

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use

Stoop

Landuyt

Paquay³

et al. 2010

Human Reproduction

View full text Add to dashboard Cite

show abstract

“…Even in the short‐term, the use of GnRH analogues requires high doses of gonadotrophins to achieve an adequate follicular response. This could be costly, not only in financial terms, but in terms of risk to patient health as the use of high doses of potent follicular stimulants increases the chance of ovarian hyperstimulation (Forman et al 1990; Bellaish‐Allart et al 1988). Over many years of using clomiphene citrate and hMG, we have not experienced a single serious case of clinical ovarian hyperstimulation syndrome; but since the beginning of this study we can report five women with severe ovarian hyperstimulation resulting from the short‐term use of GnRH analogue with hMG, together with several women with mild to moderate hyperstimulation.…”

Section: Discussionmentioning

confidence: 99%

The use of the GnRH analogue buserelin for IVF—does it improve fertility?

Shelton¹,

Fishel²,

Jackson³

et al. 1991

BJOG

View full text Add to dashboard Cite

Objective-To determine the effect of a short course of the GnRH analogue buserelin and human menopausal gonadotrophin (hMG), for ovarian stimulation in our IVF programme, on reproductive endocrinology and pregnancy rates compared with conventional clomiphene citrate and hMG treatment. Design-Prospective randomized allocation to one of two ovulation stimulation regimens. Setting-Fertility clinic. Subjects-373 infertile couples with various factors associated with their subfertility. All the women were <46 years of age and had normal menstrual cycles.Intervention-The first group (n = 151) was given clomiphene citrate (CC) from days 2-6 of the menstrual cycle and hMG from day 5 onwards (CC/hMG). The second group (n = 222) was given buscrelin from days 1-3 and hMG from day 2 (buserelin/hMG). Main outcome measures-Concentration of plasma luteinizing hormone (LH), oestradiol (EJ and progesterone, number of ovulatory follicles induced and the Occurrence of pregnancy. Results-Plasma LH, E, and progesterone concentrations wcre reduced in the late follicular phase after buserelidhMG compared with CChMG. Buserelid hMG promoted the development of more follicles than CChMG. The overall pregnancy rate after buserelidhMG was not significantly different from that following CUhMG treatment. Conclusion-The chance of pregnancy is not improved by the short-term use of buserelin with hMG, provided adequate follicular phase management is maintained.The use of the gonadotrophin releasing hormone (GnRH) analogue (buserelin) combined

show abstract

“…Tiitinen et al 79 went on to show a favorable pregnancy rate of 32.6% after subsequent naturalcycle replacement of frozen, thawed embryos, and Pattinson 80 showed a similar pregnancy rate of 25.2% per thawed embryo transfer. Belaisch-Allert et al 81 found that aspirating all but one follicle 35 hours after hCG injection and instructing the patient to have intercourse one day after hCG could lead to successful pregnancies. Another method that has been attempted is to aspirate one half of the follicles 12 hours after hCG and performing the regular oocyte retrieval 36 hours after hCG in high-risk patients.…”

Section: Preventionmentioning

confidence: 99%

Prevention and Treatment of Ovarian Hyperstimulation Syndrome

Dourron¹,

Williams²

1996

Semin Reprod Med

View full text Add to dashboard Cite

Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovarian stimulation. Although the milder form is more common, particularly among patients undergoing gonadotropin stimulation for assisted reproductive technology, the severe form is rare. Classification schemes are clinically directed and useful in diagnosis and management of moderate and severe cases. The ovarian renin-angiotensin system, as well as vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) offers attractive theories as to the pathogenesis of this disorder. Unfortunately, clinical applications of these findings are not yet available. Possible prevention measures would include identification of patients at high risk, withholding human chorionic gonadotropin (hCG), using a gonadotropin-releasing hormone agonist to trigger ovulation, using a smaller dose of hCG, controlled gonadotropin drift, or avoidance of fresh embryo transfer by cryopreservation and frozen embryo transfer at a later date. Management of moderate to severe OHSS rests upon the principles of expanding intravascular volume and maintaining adequate urine output.

show abstract

Selective oocyte retrieval: a new approach to ovarian hyperstimulation

Cited by 22 publications

References 4 publications

Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use

Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use

The use of the GnRH analogue buserelin for IVF—does it improve fertility?

Prevention and Treatment of Ovarian Hyperstimulation Syndrome

Contact Info

Product

Resources

About